FDA Recalls 600,000 Defective Prescription Inhalers

(KMJ) – The FDA is recalling 600,000 defective prescription inhalers from GlaxoSmithKline for a “defective delivery system” due to a leak.

Reuters reports drugmaker GSK is trying to figure out what caused the problem, and is pulling the inhalers from hospitals, pharmacies, retailers and wholesalers.

The recalled inhalers have a lot number of 6ZP9848, 6ZP0003 or 6ZP9944 and expire in March or April of 2018.